Serina Therapeutics Inc.

11/12/2025 | Press release | Distributed by Public on 11/12/2025 11:37

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.
The Board of Directors of Serina Therapeutics, Inc. (the "Company") held the Company's 2025 Annual Meeting of the Stockholders (the "Annual Meeting") on November 7, 2025. A quorum was present at the meeting. The final results of voting for each matter submitted to a vote of stockholders at the Annual Meeting are set forth below.
Proposal 1
Election of Two Directors
Voting results for the election of directors were as follows:
Nominees
For
Withheld
Broker Non-Votes
Steve Ledger
4,165,885
93,287
2,681,141
Karen J. Wilson
4,169,893
89,279
2,681,141
Accordingly, both of the Company's nominees were elected to serve as directors of the Company until the 2028 Annual Meeting of Stockholders or until their respective successors are appointed, elected and qualified.
Proposal 2
Ratification of the Appointment of Auditors
Ratification of the appointment of Frazier & Deeter, LLC as the Company's independent registered public accounting firm for the 2025 fiscal year was approved by the following vote:
For
Against
Abstain
Broker Non-Votes
6,544,850
377,827
17,636
-
Proposal 3
Approval of the Convertible Note and Warrants Proposal
As described in the Company's Proxy Statement, the issuance of common stock in connection with the exercise of the Convertible Note and Warrants was approved by the following vote:
For
Against
Abstain
Broker Non-Votes
4,149,038
108,481
1,653
2,681,141
Serina Therapeutics Inc. published this content on November 12, 2025, and is solely responsible for the information contained herein. Distributed via Edgar on November 12, 2025 at 17:37 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]